Advertisement
JAZZ vs ZYME
Which Stock Would AI Choose? Jazz Pharmaceuticals (JAZZ) vs. Zymeworks (ZYME) Stock Comparison
Key Takeaways
- JAZZ is a profitable, commercial-stage biopharma with diversified neuroscience and oncology revenue, while ZYME is a smaller, royalty-driven biotech still reporting net losses.
- The two companies are strategic partners: Zymeworks developed Ziihera (zanidatamab), which Jazz commercializes, linking their clinical catalysts.
- Jazz delivered double-digit revenue growth in recent quarters and raised its full-year sales outlook, while Zymeworks is repositioning around milestone and royalty cash flows.
- Jazz trades as a large-cap value-plus-growth name; Zymeworks trades as a higher-beta, catalyst-dependent small cap.
- Wall Street consensus is "Buy" on JAZZ and "Strong Buy" on ZYME, though the two carry very different risk profiles.
Introduction
Investors evaluating the biopharmaceutical sector often weigh profitable, established franchises against earlier-stage, catalyst-driven names. That contrast is especially clear in a JAZZ versus ZYME stock comparison. Jazz Pharmaceuticals is a global commercial enterprise with diversified product revenue, while Zymeworks is a clinical-stage biotech whose value hinges on partnerships, milestones, and royalties. Because the two companies are also collaborators, their fates are partly intertwined. This analysis is most relevant to traders and investors seeking to compare relative performance, market positioning, and risk-reward profiles across the spectrum of drug developers.
JAZZ Overview and Recent Performance
JAZZ (Jazz Pharmaceuticals plc) is a global biopharmaceutical company focused on neuroscience and oncology. Its commercial portfolio spans sleep medicines such as Xywav, the epilepsy therapy Epidiolex, and oncology products including Zepzelca, Rylaze, and Ziihera. In recent quarters, the company reported strong top-line growth driven by both franchises, with second-quarter revenue rising roughly 16% year over year to about $1.21 billion and oncology sales expanding about 32%. Jazz raised its full-year sales outlook, a move that supported positive sentiment even as a modest earnings-per-share (EPS) shortfall reflected acquisition-related research and development costs. Recent market activity shows a stock that has climbed substantially over the trailing year but cooled somewhat in the near term as investors assess how much growth is already reflected in the price. A planned leadership transition in its commercial organization and an FDA (U.S. Food and Drug Administration) priority review for Ziihera in gastroesophageal adenocarcinoma (GEA) are among the factors shaping the current narrative.
ZYME Overview and Recent Performance
ZYME (Zymeworks Inc.) is a clinical-stage biotechnology company that engineers antibody-based therapeutics, including antibody-drug conjugates (ADCs, which deliver a toxic payload directly to cancer cells). Its model increasingly emphasizes asset and royalty aggregation: the company developed Ziihera and licensed it to Jazz and BeOne Medicines, positioning it to receive milestone payments and royalties rather than carrying full commercialization costs. Recent quarters show revenue that fluctuates with collaboration activity and a net loss reflecting continued research investment. Management has sought to diversify toward cash flow, notably through a proposed acquisition of Theravance Biopharma, backed partly by a non-recourse note, and a share repurchase program. The company maintains a solid cash balance and has guided that its resources, combined with anticipated regulatory milestone payments, can fund operations for several years. Sentiment has been shaped by Ziihera's positive Phase 3 data and progress across its internal ADC pipeline.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own strategy, timeframe, performance statistics, and watchlist of securities. Because market conditions change constantly, only a small subset of these bots is selected for the curated Trending AI Robots section, which highlights the systems currently best suited to prevailing market dynamics. The bots span a wide range of trading styles and risk profiles, from short-term momentum strategies to longer-horizon trend-following approaches, giving traders flexibility in how they deploy automated signals. Whether you follow large-cap names like JAZZ or catalyst-driven biotechs like ZYME, exploring this section can help you identify AI-driven strategies aligned with your objectives. You can review the latest curated selections on the Trending AI Robots page.
Head-to-Head Comparison
The most fundamental contrast between these two names is scale and stage of maturity. JAZZ generates over $1 billion in quarterly revenue, is profitable on an adjusted basis, and funds growth from internal cash flow. ZYME, by contrast, relies on collaborations, milestones, and royalties, and continues to report net losses as it advances its pipeline. Sector exposure differs as well: Jazz spans both neuroscience and oncology, offering diversification across chronic and cancer indications, whereas Zymeworks is concentrated in oncology and ADC technology.
Growth drivers also diverge. Jazz's catalysts include expanding label opportunities for Ziihera and Zepzelca and new launches such as Modeyso. Zymeworks' upside is more directly tied to the same Ziihera program, plus its internal ADC candidates and the Theravance integration. On risk, JAZZ faces generic erosion in its oxybate franchise and patent expiries, while ZYME carries typical clinical-stage and financing risk, partially offset by a royalty-oriented structure and repurchases. Market sentiment assigns JAZZ a consensus "Buy" with a target implying meaningful upside, while ZYME carries a "Strong Buy" consensus and a higher implied upside reflecting its smaller base and higher beta.
Tickeron AI Verdict
On a probabilistic basis, Tickeron's AI framework would likely favor JAZZ for trend consistency, stability, and fundamental positioning. Jazz combines established, recurring revenue with a defined set of near-term catalysts and a profitable operating base, characteristics that tend to align with smoother, more persistent price trends. ZYME offers greater potential percentage upside and has constructive analyst support, but its thinner revenue base and dependence on milestone timing introduce more variability. The verdict therefore leans toward JAZZ as the more stable AI candidate, while recognizing that ZYME may appeal to traders seeking higher-beta, catalyst-driven exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Hold and ZYME is a StrongBuy.
Momentum Indicator for JAZZ turns negative, indicating new downward trend
JAZZ saw its Momentum Indicator move below the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In 56 of the 96 cases, the stock moved further down in the following days. The odds of a decline are at 58%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for JAZZ entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JAZZ's RSI Oscillator exited the oversold zone, 19 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 178 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
JAZZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (2.988). P/E Ratio (13.936) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ZYME in +10.08% Uptrend, advancing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZYME advanced for three days, in 251 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZYME as a result. In 71 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on October 20, 2026. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
ZYME moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ZYME crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
ZYME broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.100) is normal, around the industry mean (2.988). P/E Ratio (-13.918) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
JAZZ | ZYME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 43 | 100 | |
SMR RATING 1..100 | 44 | 98 | |
PRICE GROWTH RATING 1..100 | 54 | 42 | |
P/E GROWTH RATING 1..100 | 97 | 62 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZYME's Valuation (83) in the Pharmaceuticals Major industry is in the same range as JAZZ (85) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew similarly to JAZZ’s over the last 12 months.
JAZZ's Profit vs Risk Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for ZYME (100) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew somewhat faster than ZYME’s over the last 12 months.
JAZZ's SMR Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for ZYME (98) in the Pharmaceuticals Major industry. This means that JAZZ’s stock grew somewhat faster than ZYME’s over the last 12 months.
ZYME's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as JAZZ (54) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew similarly to JAZZ’s over the last 12 months.
ZYME's P/E Growth Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for JAZZ (97) in the Pharmaceuticals Other industry. This means that ZYME’s stock grew somewhat faster than JAZZ’s over the last 12 months.
| JAZZ | ZYME | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 66% | N/A |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 84% |
| MACD ODDS (%) | N/A | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 83% |
| Advances ODDS (%) | 18 days ago 61% | 2 days ago 85% |
| Declines ODDS (%) | 4 days ago 55% | 9 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JAZZ’s FA Score shows that 0 FA rating(s) are green while ZYME’s FA Score has 0 green FA rating(s).
- JAZZ’s FA Score: 0 green, 5 red.
- ZYME’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JAZZ’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 4 bullish TA indicator(s).
- JAZZ’s TA Score: 4 bullish, 3 bearish.
- ZYME’s TA Score: 4 bullish, 5 bearish.
Price Growth
JAZZ (@Biotechnology) experienced а +1.11% price change this week, while ZYME (@Biotechnology) price change was +13.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
JAZZ is expected to report earnings on Nov 02, 2026.
ZYME is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ZYME and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with JAZZ. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then JAZZ could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | +4.48% | ||
| JAZZ - ZYME | 52% Loosely correlated | -0.84% | ||
| REPL - ZYME | 46% Loosely correlated | +2.63% | ||
| VSTM - ZYME | 44% Loosely correlated | -1.39% | ||
| ENTA - ZYME | 43% Loosely correlated | -3.08% | ||
| MLTX - ZYME | 40% Loosely correlated | +3.20% | ||
More | ||||